A phase Ib study of a single priming dose of 177Lu-PSMA617 coupled with pembrolizumab in metastatic castration resistant prostate cancer (mCRPC)

被引：0

作者：

Aggarwal, R. ^{[1
]}

Trihy, L. ^{[2
]}

Hernandez Romero, E. ^{[2
]}

Sam, S. Luch ^{[1
]}

Rastogi, M. ^{[1
]}

De Kouchkovsky, I. ^{[3
]}

Small, E. J. ^{[4
]}

Feng, F. ^{[5
]}

Kwon, D. ^{[3
]}

Friedlander, T. ^{[3
]}

Borno, H. T. ^{[3
]}

Bose, R. ^{[6
]}

Chou, J. ^{[3
]}

Koshkin, V. S. ^{[7
]}

Desai, A. ^{[8
]}

Feng, S. ^{[2
]}

Angelidakis, A. ^{[2
]}

Johnson, M. S. ^{[9
]}

Fong, L. ^{[10
]}

Hope, T. ^{[11
]}

机构：

[1] Univ Calif San Francisco, Med Dept, Parnassus Campus, San Francisco, CA USA

[2] UCSF Univ Calif San Francisco, Canc Ctr, San Francisco, CA USA

[3] UCSF Univ Calif San Francisco, Med, San Francisco, CA USA

[4] UCSF Helen Diller Family Comprehens Canc Ctr, Comprehens Canc Ctr, San Francisco, CA USA

[5] UCSF Univ Calif San Francisco, Radiat Oncol, Parnassus Campus, San Francisco, CA USA

[6] UCSF Univ Calif San Francisco, Anat, San Francisco, CA USA

[7] UCSF Helen Diller Family Comprehens Canc Ctr, Div Med Oncol, San Francisco, CA USA

[8] Univ Calif San Francisco, Dept Med, San Francisco, CA USA

[9] UCSF Med Ctr Mission Bay, Genitourinary Oncol Dept, San Francisco, CA USA

[10] UCSF Diabet Teaching Ctr, Med Dept, San Francisco, CA USA

[11] UCSF Univ Calif San Francisco, Radiol, San Francisco, CA USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1379P

引用

页码：S1173 / S1173

页数：1

共 50 条

[41] Effectiveness of 177Lu PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
Gunalp, Bengul
Emer, Mustafa
Ozaydin, Sukru
Alagoz, Engin
Ince, Semra
Ayan, Asli
Alkan, Sumeyye
Mahmudov, Sarkhan
Okuyucu, Kursat
JOURNAL OF NUCLEAR MEDICINE, 2018, 59
[42] LuCAB: A phase I/II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Kostos, Louise Kathleen
Buteau, James Patrick
Kong, Grace
Yeung, Theresa
Di Iulio, Juliana
Fahey, Michael T.
Fettke, Heidi
Furic, Luc
Hofman, Michael S.
Azad, Arun
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[43] Impact of race on outcomes to 177Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC).
Rami, Avina
Ng, Thomas S. C.
Rothmann, Emily
Stoltenberg, Hailey
Wolanski, Andrew
Ritzer, Jolivette
Choudhury, Atish Dipankar
Gao, Xin
Haberman, Veronica
Kako, Bashar
Kilbridge, Kerry L.
Morgans, Alicia K.
O'Shea, Aileen
Taplin, Mary-Ellen
Jacene, Heather
Ravi, Praful
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 27 - 27
[44] Association of tumor genetics with outcomes in patients (pts) with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA-617.
Panian, Justine
Henderson, Nicholas
Barata, Pedro C.
Bilen, Mehmet Asim
Graham, Laura
Heath, Elisabeth I.
Herchenhorn, Daniel
Hwang, Clara
Kilari, Deepak
Koshkin, Vadim S.
Nauseef, Jones T.
Sokolova, Alexandra
Zakharia, Yousef
Schweizer, Michael Thomas
Dorff, Tanya B.
Armstrong, Andrew J.
Alva, Ajjai Shivaram
Mckay, Rana R.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[45] Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration- resistant prostate cancer: an open-label, dose-expansion, phase 1trial
Aggarwal, Rahul
Starzinski, Stephanie
de Kouchkovsky, Ivan
Koshkin, Vadim
Bose, Rohit
Chou, Jonathan
Desai, Arpita
Kwon, Daniel
Kaushal, Samuel
Trihy, Lauren
Rastogi, Medini
Ippisch, Robin
Aslam, Maya
Friedlander, Terence
Feng, Felix
Oh, David
Cheung, Alexander
Small, Eric
Evans, Michael
Fong, Lawrence
Hope, Thomas A.
LANCET ONCOLOGY, 2023, 24 (11): : 1266 - 1276
[46] Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy
Fadi Khreish
Niklas Kochems
Florian Rosar
Amir Sabet
Martin Ries
Stephan Maus
Matthias Saar
Mark Bartholomä
Samer Ezziddin
European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 103 - 112
[47] Therapeutic efficacy and clinical outcome of 177Lu-PSMA-617/225Ac-PSMA-617 radioligand therapy in metastatic castration resistant prostate cancer (mCRPC) - single institutional experience from India
Kalra, Kriti
JOURNAL OF NUCLEAR MEDICINE, 2023, 64
[48] Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy
Khreish, Fadi
Kochems, Niklas
Rosar, Florian
Sabet, Amir
Ries, Martin
Maus, Stephan
Saar, Matthias
Bartholomae, Mark
Ezziddin, Samer
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (01) : 103 - 112
[49] Excellent Response to Lower Dose of 177Lu-PSMA-617 in a Metastatic Castration-Resistant Prostate Cancer Patient With a Transplanted Kidney
Norouzi, Ghazal
Aghdam, Ramin Akbarian
Hashemifard, Hamidreza
Pirayesh, Elahe
CLINICAL NUCLEAR MEDICINE, 2019, 44 (06) : 483 - 484
[50] Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC)
Vlachostergios, Panagiotis J.
Goswami, Sukanya
Niaz, Muhammad Junaid
Thomas, Charlene
Christos, Paul J.
Osborne, Joseph
Vallabhajosula, Shankar
Molina, Ana M.
Sternberg, Cora N.
Singh, Sharon
Tan, Angela
Patel, Amie
Nanus, David M.
Bander, Neil Harrison
Tagawa, Scott T.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)

← 1 2 3 4 5 →